Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

Master the differences between NumPy arrays and Python lists with this clear guide. Learn when to use each, understand performance benefits, and see practical examples to write more efficient and ...

The ARAQYS-D3 mission by Dcubed will demonstrate the ability to manufacture a solar array 15 meters long in orbit. Credit: Dcubed BREMEN, Germany — German satellite component company Dcubed is moving ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...

Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product ...